Metabolic cardiovascular diseases are the most common cause of morbidity and mortality worldwide, representing a major public health challenge. Some clinical, genetic, and environmental risk factors related to metabolic cardiovascular diseases have been well-established, such as obesity, diabetes, cigarette smoking, air pollution exposures, diet and physical activity. However, research on metabolic cerebrovascular diseases is still insufficient. Recent studies suggested that muti-omics (including metabolomics, proteomics, and radiomics) imbalance also played an important role in the development and progression of diseases. Combining multi-omics data with clinical, genetic, lifestyle, and environmental risk factors might help to improve the evaluation of the risk of metabolic cardiovascular and cerebrovascular diseases. Moreover, exploring the independent and joint effect of multi-omics, genetic, lifestyle, and environmental risk factors on the morbidity and mortality of metabolic cardiovascular and cerebrovascular diseases will help to assess the modifiable risk, take strategies to prevent the metabolic cardiovascular and cerebrovascular diseases, and reduce the mortality. In this project, we aim to investigate the associations of multi-omics, genetic, lifestyle and environmental risk factors as well as their interactions with the morbidity and mortality of metabolic cardiovascular and cerebrovascular diseases; to evaluate the modification effect of genetic susceptibility on above associations; and to explore biomarkers that may play a role in the occurrence, progression, and prognosis of metabolic cardiovascular and cerebrovascular diseases. Given that cognitive impairment is closely related to the occurrence of cerebrovascular diseases, we will also focus on the role of above associations in the occurrence of cognitive impairment.
Our project is expected to last 36 months, and we will endeavor to contribute to the knowledge surrounding the impact of multi-omics, genetic, lifestyle, and environmental risk factors on the morbidity and mortality of metabolic cardiovascular and cerebrovascular diseases and cognitive impairment, and therefore improve health status and extend healthspan.
